Douglas S. Ingram, President & CEO at Sarepta Therapeutics, Inc. (SRPT), bought 32,504 shares at $123.41 ($4.0M) on 2019-08-12, disclosed to the SEC on 2019-08-12.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $122.76 | 8,460 | $1.0M | 26.0% |
| 2 | $122.76 | 8,460 | $1.0M | 26.0% |
| 3 | $123.41 | 7,792 | $962K | 24.0% |
| 4 | $123.41 | 7,792 | $962K | 24.0% |
| Total | $123.07 avg | 32,504 | $4.0M | 100% |
| Filing → |
| RLAY | BUY | 2020-07-21 | $500K | — | Filing → |
| SRPT | BUY | 2018-10-30 | $4.0M | — | Filing → |
| SRPT | BUY | 2018-08-16 | $2.0M | — | Filing → |